A Study of the Effectiveness in Patients With Gastric or Gastroesophageal Junction Cancer With Nivolumab by Itself or in Combination With Ipilimumab and in Patients With Esophageal Cancer With Combination of Nivolumab and Ipilimumab.

• Status: Not yet recruiting
• Trial end date: 0000-00-00
• Target enrollment: 939
• Participant gender: All

Summary

The main purpose of this study for patients with gastric or gastroesophageal cancer is to evaluate how well the tumor is responding to treatment with nivolumab by itself, or in combination with ipilimumab.

For patients with esophageal cancer, the main purpose is to evaluate how well the tumor is responding to treatment with the combination of nivolumab and ipilimumab.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Collaborator: Ono Pharmaceutical Co. Ltd
• Treatments: Antibodies, Monoclonal; Nivolumab
• Last Updated: 2017-05-01

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Must have gastric, esophageal or gastroesophageal junction cancer that cannot be operated on, that is advanced or has spread out

Exclusion Criteria

• Presence of tumor cells in the brain or spinal cord that have not been treated

• Active known or suspected autoimmune disease

Other protocol defined inclusion/exclusion criteria could apply